BioAtla adopts 1-for-50 reverse stock split via merger after Nasdaq policy reversal; delisting risk

BioAtla, Inc.

Issued one share of super-voting Series A Preferred to pass reverse split (100M votes for), then redeemed it for $0.01.
Board chose not to implement reverse split; Nasdaq said super-voting use now violates Rule 5640 without public notice.
Entered merger for 1-for-50 reverse split; requires majority stockholder vote at special meeting.
AIRC confirmed investment in Inversagen AI; BioAtla to receive $5M for 4.375% of SPV common units.
Nasdaq compliance deadline Feb 2; company believes Nasdaq's delays and policy change were in error and harmful.

item 5.03 item 5.07 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BioAtla, Inc.: Filed Certificate of Elimination to remove Series A Junior Preferred Stock from the Amended and Restated Certificate of Incorporation (effective 2026-01-30).

Change: charter amendment
Effective: 2026-01-30

Exact text from the filing

On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).

View on SEC.gov

Browse all governance changes →

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-031942

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.